Physician profile
William Mania
NPI 1770599326
$3,004.90
in general payments reported to CMS, 2019-2025
26 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $409 · 2021: $399 · 2022: $299 · 2023: $821 · 2024: $272 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $505.06 | 2023-2025 | |
| Abbvie INC. | $442.90 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $432.90 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $285.23 | 2020-2021 | |
| Eisai INC. | $155.33 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $153.71 | 2019-2021 | |
| Axsome Therapeutics, INC. | $135.29 | 2023 | Sunosi |
| Boston Scientific Corporation | $124.99 | 2019 | |
| Idorsia Pharmaceuticals US INC | $115.29 | 2023 | Quviviq |
| Stryker Corporation | $112.16 | 2019 | |
| Lilly USA, LLC | $109.59 | 2019-2023 | Jardiance, Emgality |
| Amgen INC. | $72.07 | 2019-2021 | |
| Scynexis, INC. | $47.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.96 | 2020-2025 | Jardiance |
| Clarus Therapeutics INC. | $37.79 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $30.04 | 2024 | Dupixent |
| Grt US Holding, INC. | $28.90 | 2022 | |
| Merck Sharp & Dohme LLC | $27.67 | 2019 | |
| Paratek Pharmaceuticals, INC. | $24.36 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $21.96 | 2020 | |
| Amryt Pharma Holdings Ltd | $21.23 | 2022 | |
| Mckesson Medical-Surgical, INC. | $20.00 | 2021 | |
| Medicure Pharma INC. | $17.23 | 2024 | Zypitamag |
| Takeda Pharmaceuticals U.S.A., INC. | $15.72 | 2021 | |
| Aytu Biopharma, INC. | $13.46 | 2020 | |
| Antares Pharma, INC. | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.